ArticleMovement disorders clinical practice2025
A Bottom-Up Analysis of the Cost of Illness of Parkinson's Disease in the Netherlands from a Societal Perspective.
Article in Movement disorders clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Modeling Framework for Economic Evaluation of Disease-Modifying Therapies in Parkinson's Disease: Evidence Review and Expert Opinion.PharmacoEconomics · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParkinson's disease (PD) places a high burden on patients, their families, healthcare systems, and society as a whole, which is rising due to the increasing prevalence of PD. There has been wide variation in the items included in previous cost of illness (COI) studies for PD, possibly underestimating the costs associated with this disease.
objectivesThis study aims to undertake a detailed estimate of the COI of PD in the Netherlands from a societal perspective.
methodsBetween November 2022 and May 2023, we conducted a cross-sectional COI study with a bottom-up, prevalence-based approach. Data were collected using a questionnaire with a recall period of three months. Costs were valued following the Dutch guideline for economic evaluations in healthcare and extrapolated to costs per year.
resultsSeventy-four patients were included, with a mean age of 65.9 years and a mean disease duration of 6.3 years. Patients in early disease stages were over-represented. COI was determined at € 14,487 per patient per year. Healthcare accounted for 55.6% of costs, followed by productivity loss (23.9%) and costs to patients and families (20.5%). The most impactful cost item was medication, followed by social productivity loss, informal care, auxiliary therapy, and work productivity loss. Alternative valuation methods for productivity led to an estimated COI of € 36,867.
conclusionsPD-COI was 30-40% higher than previously determined in comparable patient groups, probably due to a more comprehensive measurement of costs. Future COI studies in PD should adopt a societal perspective and include all relevant cost items.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.